20 results on '"Gramatzki, Martin"'
Search Results
2. Targeting of CD317 by the immunotoxin HM1.24-ETA’ to allow immunotherapy in glioblastoma patients.
3. Potent targeting of B cell lymphoma and plasma cell tumors by a tetravalent, Fc-engineered antibody directed against the glycoantigen CD75s.
4. Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.
5. Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.
6. MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study.
7. MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.
8. Anti-myeloma activity of the novel ADCC-optimized human CD54 (ICAM-1) antibody MSH-TP15e.
9. A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
10. A novel human Fc-optimized ICAM-1/CD54 antibody (MSH-TP15e) with potent anti-myeloma activity in vitro and in vivo.
11. Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).
12. Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor.
13. Identification and activity of the novel antibody MSH-TP15 by a cell-based phage display screening approach.
14. Blockade of the PI3K-alpha isoform to inhibit myeloma cells.
15. CD96 antibody TH-111 for detection of AML leukemic stem cells, and purging of autografts for stem cell transplantation.
16. Effect of targeting the gp130 receptor rather than the IL-6 receptor on control of multiple myeloma growth.
17. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
18. HM1.24/CD317-directed immunotoxin to eliminate malignant plasma cells in vitro and in vivo.
19. Preclinical activity of the JAK1/2 inhibitor ruxolitinib on malignant plasma cell growth and survival.
20. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.